Rocket Lab shares surged approximately 30% in a single week during December, driven by reports of a forthcoming SpaceX IPO valued up to $1.5 trillion. That move contributed to a 174% gain over the full year, underscoring renewed appetite for small- and medium-lift launch providers. The company completed a record 21 Electron missions in 2025, adding five more launches than its previous high in 2024, bolstering its backlog to over $2 billion following an $816 million satellite contract. Analysts highlight that this momentum has translated into bullish consensus ratings and ambitious revenue projections.

Rocket Lab’s reusable medium-lift Neutron vehicle, designed to lift up to 13,000 kg to low-Earth orbit, has been postponed multiple times—from an initial debut target in 2024 to late 2025, and now into mid-2026 or later. Each quarter of delay is estimated to cost an additional $15 million, potentially pushing the first flight into 2027 if engine integration challenges persist. Even a brief slip beyond the first-quarter window could trigger a significant market reaction, given that Neutron contracts are priced at $50 million to $55 million apiece and represent Rocket Lab’s gateway into higher-margin, large-scale missions.

Neutron faces formidable competitors: SpaceX’s Falcon 9 currently delivers 17,500 kg to low-Earth orbit and Starship aims for 150 t, while per-flight costs on Falcon 9 rideshares run approximately $67 million to $70 million. With internal launch costs estimated near $15 million, SpaceX can undercut Neutron’s pricing if strategic. Firefly Aerospace is also targeting a late-2026 debut of its Eclipse medium-lift rocket. Industry experts caution that unless Rocket Lab’s maiden Neutron flight is flawless, government and commercial customers may default to incumbents with longer track records.

Despite record revenue growth, Rocket Lab’s cumulative Neutron development spending approaches $360 million by year-end 2025, sustaining negative operating cash flow. Continued R&D and capital expenditures could necessitate additional equity raises, risking dilution at current lofty valuations—approximately 48 times forward revenue forecasts. While consensus revenue estimates foresee sales more than doubling to $1.2 billion by 2027, any further launch delays, supply-chain constraints or regulatory setbacks at Wallops Island could compress margins and derail growth assumptions.